India Pharma Outlook Team | Wednesday, 03 June 2026
Johnson & Johnson India has introduced its advanced Pulsed Field Ablation technology in India, marking a significant development in the country’s cardiac care landscape.
The launch is expected to enhance treatment options for patients suffering from atrial fibrillation (AFib), a common heart rhythm disorder treatment area that increases the risk of stroke, heart failure, and other cardiovascular complications.
The introduction of the technology positions India among key global markets adopting next-generation electrophysiology technology solutions for heart rhythm management.
The newly launched platform is designed to treat AFib through a catheter-based ablation procedure that uses electrical pulses instead of extreme heat or cold to target problematic heart tissue.
Known as Pulsed Field Ablation technology, the approach is increasingly being recognised for its precision and reduced risk of damage to surrounding tissues compared to conventional thermal ablation techniques.
Also Read: Akums Receives European CEP Approval for Cefpodoxime Proxetil
The technology introduced by Johnson & Johnson MedTech is based on its VARIPULSE platform, which integrates with advanced cardiac mapping systems to improve procedural accuracy and physician control during treatment. The system is designed to provide real-time visualisation of heart structures, enabling specialists to identify abnormal electrical pathways and perform targeted ablation more efficiently.
Atrial fibrillation affects millions globally and is becoming an increasing health concern in India due to changing lifestyles, rising cardiovascular diseases, and ageing populations. In AFib patients, irregular electrical signals in the heart cause rapid and uncoordinated beating, often leading to fatigue, dizziness, shortness of breath, and elevated stroke risk if left untreated.
Traditional ablation procedures have relied on thermal energy sources such as radiofrequency or cryoablation, but these methods may sometimes affect nearby tissues including nerves or the oesophagus. Advanced cardiac technology such as pulsed field ablation seeks to minimise such complications by selectively targeting cardiac muscle cells while preserving surrounding structures.
Johnson & Johnson has been expanding its electrophysiology portfolio globally, with the company highlighting the role of PFA in making cardiac procedures faster, safer, and more reproducible. Internationally, the platform has already been introduced across multiple markets in Asia-Pacific, Europe, and North America, supported by growing clinical data demonstrating procedural efficiency and favourable patient outcomes.
The India launch also reflects growing demand for cardiovascular healthcare India solutions as hospitals increasingly invest in specialised cardiac rhythm management services. Experts believe the availability of PFA technology could strengthen treatment outcomes, especially for patients who do not respond adequately to medication-based therapy for AFib. This advancement is expected to support AFib treatment India through more precise and minimally invasive interventions.
Healthcare providers are expected to gradually integrate the technology into major tertiary care centres and specialised cardiac hospitals, supported by physician training and growing awareness around electrophysiology interventions. As India continues to witness a rise in cardiac disorders, the adoption of minimally invasive heart procedure technologies such as pulsed field ablation could play an important role in improving patient safety and expanding access to modern cardiac care.
.jpg)
